deucravacitinib,apremilast
bms,amgen
['psoriasis', 'deucrava', 'deucra', '$bmy', 'bristol']
$bmy bristol myers squibb announces new sotyktu (deucravacitinib) long-term data showing clinical efficacy maintained for up to two years with continuous treatment in moderate-to-severe plaque psoriasis 
¬ Retweeting Bloomberg's Feed all in one place.

¬ Market Updates

¬ I'm Barry Bloomberg putting out the fastest updates!

¬ Making your life easier.